Clinical Digest: A Comprehensive Review of Recent Abbvie Patents (2026-04)
This compilation provides an overview of Abbvie‘s latest patent inventions. Alongside these patents are potentially related patents, which may include work from Abbvie or other entities exploring similar therapeutic areas. This resource aims to offer researchers, clinicians, investors, and the broader public insights into Abbvie’s current research and development pipeline. By presenting patent details alongside related intellectual property (regardless of origin), this compilation facilitates a broader understanding of Abbvie’s strategic focus and how it potentially compares to direct and indirect competitors in these therapeutic spaces. This information can be valuable for identifying emerging trends in drug development, assessing the commercial potential of specific research programs, and understanding the broader landscape of scientific contributions related to Abbvie’s patent inventions. (Last updated on: 2026-04-05)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: A Comprehensive Review of Recent Abbvie Patents (2026-04)
| Title | Applicant/Assignee | Filing Date | Publish Date | Grant Date | |
|---|---|---|---|---|---|
| 1 | Dosing Regimens for Elagolix Related Patents View Abstract: The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for … |
ABBVIE | 2025-08-26 | 2026-04-02 | |
| 2 | Methods of Treating Heavy Menstrual Bleeding Related Patents View Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an … |
ABBVIE | 2025-08-15 | 2026-04-02 | |
| 3 | PSMA-STEAP1 DUAL VARIABLE DOMAIN IMMUNOGLOBULIN (DVD-Ig) MOLECULES AND DRUG CONJUGATES Related Patents View Abstract: The present disclosure provides dual variable domain immunoglobulin (DVD-Ig) molecules that bind to human STEAP1 and human PSMA and their drug conjugates, and methods of using the … |
ABBVIE | 2024-11-25 | 2026-04-02 | |
| 4 | ANTI-ALPHA-4-BETA-7 ANTIBODIES Related Patents View Abstract: The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection. … |
ABBVIE | 2025-03-19 | 2026-03-05 | |
| 5 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS Related Patents View Abstract: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis. … |
DISC MEDICINE; ABBVIE; ABBVIE DEUTSCHLAND | 2025-11-03 | 2026-02-26 | |
| 6 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS Related Patents View Abstract: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis. … |
DISC MEDICINE; ABBVIE; ABBVIE DEUTSCHLAND | 2025-06-06 | 2026-02-19 | |
| 7 | Anti-Sars-COV-2 Antibodies and Uses Thereof Related Patents View Abstract: Provided herein are monoclonal antibodies that specifically bind to an anti-SARS-CoV-2 spike(S) protein, and methods of using said antibodies. … |
ABBVIE | 2025-07-30 | 2026-02-05 | |
| 8 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3′,2′:5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS Related Patents View Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R have any of the values defined in the specification, and pharmaceutically acceptable salts … |
ABBVIE | 2025-07-02 | 2026-01-29 | |
| 9 | ANTI-C-MET ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs. … |
ABBVIE | 2025-10-03 | 2026-01-22 | |
| 10 | Levodopa and Carbidopa Intestinal Gel and Methods of Use Related Patents View Abstract: The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson’s disease … |
ABBVIE | 2025-09-19 | 2026-01-15 | |
| 11 | EXTENDED RELEASE UPADACITINIB FORMULATIONS Related Patents View Abstract: The disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, wherein the solid dosage form provides … |
ABBVIE | 2025-09-09 | 2026-01-08 | |
| 12 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER Related Patents View Abstract: Drug delivery reservoir for delivery of a beneficial agent to a user includes a drug delivery reservoir housing having a fluid reservoir defined therein. The drug delivery … |
ABBVIE | 2025-07-25 | 2026-01-08 | |
| 13 | RISANKIZUMAB COMPOSITIONS Related Patents View Abstract: The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity. … |
ABBVIE | 2023-06-15 | 2026-01-01 | |
| 14 | WEARABLE AUTOMATIC INJECTION SYSTEM AND APPARATUS Related Patents View Abstract: A wearable automatic injection device is provided for administering a final medicament to a patient. The wearable automatic injection device comprises a housing, an injection … |
ABBVIE | 2025-05-22 | 2025-12-11 | |
| 15 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS Related Patents View Abstract: Provided herein is a process for the preparation of an apoptosis-inducing agent, and chemical intermediates thereof. Also provided herein are novel chemical intermediates related … |
ABBVIE | 2022-08-25 | 2025-12-04 | |
| 16 | ENZYME COMPOSITIONS WITH REDUCED VIRAL AND MICROBIAL CONTAMINATION Related Patents View Abstract: The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for … |
ABBVIE | 2025-05-23 | 2025-11-13 | |
| 17 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT Related Patents View Abstract: Salts and crystalline forms of … |
ABBVIE | 2024-12-13 | 2025-11-06 | |
| 18 | RISANKIZUMAB COMPOSITIONS Related Patents View Abstract: The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity. … |
ABBVIE | 2025-04-24 | 2025-10-30 | |
| 19 | Tiparp Inhibitor Compounds Related Patents View Abstract: The present disclosure provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit the activity of TIPARP, wherein the variables have any of … |
ABBVIE | 2025-04-24 | 2025-10-30 | |
| 20 | METHODS OF TREATMENT USING ANTI-SEZ6 ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The present application pertains to, among other things, improved methods of treating advanced solid tumors, including small cell lung cancer (“SCLC”), relapsed/refractory (R/R) … |
ABBVIE | 2025-04-21 | 2025-10-23 | |
| 21 | PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION Related Patents View Abstract: The present disclosure relates to compositions of levodopa 4′-monophosphate and carbidopa 4′-monophosphate having a weight by weight ratio of about 20:1 and methods of treating … |
ABBVIE | 2025-03-11 | 2025-10-23 | |
| 22 | RISANKIZUMAB COMPOSITIONS Related Patents View Abstract: The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity. … |
ABBVIE | 2025-04-25 | 2025-10-09 | |
| 23 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE Related Patents View Abstract: The present disclosure provides for compounds of Formula (I) wherein A , A , A , A , A , A , A , R , R , R , R , R , R , R , R , R , R , W, X, and Y have any of the values defined … |
ABBVIE et. al. | 2024-11-19 | 2025-10-09 | |
| 24 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS Related Patents View Abstract: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis. … |
DISC MEDICINE; ABBVIE; ABBVIE DEUTSCHLAND | 2025-06-05 | 2025-10-02 | |
| 25 | PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY Related Patents View Abstract: Pump includes a motor, a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially-outward projection … |
ABBVIE | 2025-03-04 | 2025-10-02 | |
| 26 | PYRIMIDINES FOR DEGRADING BRUTON’S TYROSINE KINASE Related Patents View Abstract: The present invention provides for compounds of formula (I) wherein R , R , R , R , R , and R , are as defined herein, and pharmaceutically acceptable salts thereof, that are … |
ABBVIE | 2024-11-13 | 2025-10-02 | |
| 27 | METHODS FOR TREATING SPINAL CORD INJURY AND PAIN Related Patents View Abstract: Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both … |
ABBVIE et. al. | 2024-11-11 | 2025-10-02 | |
| 28 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or … |
CALICO LIFE SCIENCES et. al. | 2022-08-10 | 2025-10-02 | |
| 29 | ANTI-EGFR ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. … |
ABBVIE | 2024-09-03 | 2025-08-21 | |
| 30 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl) pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2025-04-17 | 2025-08-07 | |
| 31 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS AND IMPROVED DRYING PROCESSES Related Patents View Abstract: Provided herein are solid compositions comprising neurotoxin serotype A (BoNT/A) and human serum albumin (HSA), wherein the solid compositions comprise a low amount of HSA … |
ABBVIE | 2025-01-17 | 2025-07-24 | |
| 32 | ANTI-EGFR ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. … |
ABBVIE | 2024-08-07 | 2025-07-03 | |
| 33 | Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis Related Patents View Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. … |
ABBVIE; NEUROCRINE BIOSCIENCES | 2024-07-31 | 2025-07-03 | |
| 34 | MEDICATION PACKAGING AND DISPENSING SYSTEM Related Patents View Abstract: A medication packaging and dispensing system is provided. The system may include a plurality of medication booklets containing medication and a tray that is configured to retain … |
ABBVIE | 2025-02-19 | 2025-06-12 | |
| 35 | PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION Related Patents View Abstract: The present disclosure relates to compositions of levodopa 4′-monophosphate and carbidopa 4′-monophosphate having a weight by weight ratio of about 20:1 and methods of treating … |
ABBVIE | 2025-02-10 | 2025-06-12 | |
| 36 | COMBINATIONS WITH AN ANTI HUMAN CD39 ANTIBODY, AN ANTI HUMAN PD-1 ANTIBODY, AND CHEMOTHERAPY IN GASTRIC CANCER Related Patents View Abstract: Provided herein are dosing and combination therapies with a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPOX in gastric cancer. Immune checkpoint inhibitors have revolutionized … |
TRISHULA THERAPEUTICS et. al. | 2023-03-06 | 2025-06-12 | |
| 37 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS Citation: 1 Related Patents View Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders. … |
ABBVIE DEUTSCHLAND et. al. | 2024-09-19 | 2025-06-05 | |
| 38 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same Related Patents View Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the … |
ABBVIE | 2024-07-08 | 2025-06-05 | |
| 39 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES Related Patents View Abstract: The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bel-xL, including compositions and methods using such … |
ABBVIE | 2024-07-01 | 2025-05-29 | |
| 40 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER Related Patents View Abstract: A device for delivering a beneficial agent is provided and generally includes a cassette, a pump, and a delivery tube. The pump includes a pump housing containing a pump assembly … |
ABBVIE | 2024-06-25 | 2025-05-29 | |
| 41 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3,-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 1 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2025-01-21 | 2025-05-22 | |
| 42 | EXTENDED RELEASE UPADACITINIB FORMULATIONS Related Patents View Abstract: The disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, wherein the solid dosage form provides … |
ABBVIE | 2025-01-17 | 2025-05-22 | |
| 43 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT Related Patents View Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid … |
ABBVIE | 2024-08-20 | 2025-05-22 | |
| 44 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. … |
ABBVIE | 2024-05-21 | 2025-05-22 | |
| 45 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Related Patents View Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from … |
GENENTECH; HOFFMANN-LA ROCHE; ABBVIE | 2025-01-17 | 2025-05-15 | |
| 46 | PROCESSES FOR PRODUCING COMPOSITIONS WITH IMPROVED SAFETY PROFILE HAVING LIPASE ACTIVITY AND COMPOSITIONS SUITABLE FOR PHARMACEUTICAL USE Related Patents View Abstract: Processes are described for producing solid or semi-solid compositions, in particular solid oral compositions for pharmaceutical use, comprising treating an enzyme or … |
ABBVIE | 2025-01-16 | 2025-05-15 | |
| 47 | BROMODOMAIN INHIBITORS Related Patents View Abstract: The present invention provides for compounds of formula (I) wherein A , A , A , A , X , X , Y , L , G , R , and R have any of the values defined thereof in the specification, and … |
ABBVIE | 2024-06-13 | 2025-05-15 | |
| 48 | SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS Related Patents View Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The … |
ABBVIE et. al. | 2024-09-23 | 2025-05-08 | |
| 49 | BROMODOMAIN INHIBITORS Related Patents View Abstract: The present invention provides for compounds of formula (I) wherein R , Y, X , X , R , R , R , R , R , and m have any of the values defined in the specification, and … |
ABBVIE | 2024-06-04 | 2025-05-08 | |
| 50 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or … |
CALICO LIFE SCIENCES et. al. | 2024-04-26 | 2025-04-17 | |
| 51 | MODULATORS OF THE INTEGRATED STRESS PATHWAY Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions. … |
CALICO LIFE SCIENCES et. al. | 2024-04-26 | 2025-04-17 | |
| 52 | SELECTIVE REDUCTION OF ANTIBODIES Related Patents View Abstract: The present disclosure provides methods for selectively reducing an antibody, comprising contacting the antibody with a reducing agent selected from the group consisting of … |
ABBVIE | 2024-02-28 | 2025-04-17 | |
| 53 | SEALING ARRANGEMENT FOR SYRINGE Related Patents View Abstract: A syringe containing a high water content product and for use in a drug infusion system is provided. The syringe includes a plunger carrying front and rear o-rings made of a diene … |
ABBVIE | 2024-05-10 | 2025-04-10 | |
| 54 | MODULATORS OF THE INTEGRATED STRESS PATHWAY Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions. … |
CALICO LIFE SCIENCES et. al. | 2024-04-26 | 2025-04-10 | |
| 55 | ANTI-AMYLOID BETA ANTIBODIES AND METHODS OF USING THE SAME Related Patents View Abstract: The present inventive concept is related to antibodies, such as recombinant humanized and monoclonal antibodies, methods of making antibodies, and methods of using antibodies, … |
ABBVIE | 2024-05-13 | 2025-03-27 | |
| 56 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE Related Patents View Abstract: The present disclosure provides for compounds of formula (I) wherein A , A , A , A , A , A , A , R , R , R , R , R , R , R , R , R , R , W, X, and Y have any of the values defined … |
ABBVIE et. al. | 2024-02-29 | 2025-03-20 | |
| 57 | Elagolix Sodium Compositions and Processes Related Patents View Abstract: The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof. … |
ABBVIE | 2024-11-20 | 2025-03-13 | |
| 58 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS Citation: 1 Related Patents View Abstract: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis. … |
DISC MEDICINE; ABBVIE; ABBVIE DEUTSCHLAND | 2024-09-25 | 2025-03-13 | |
| 59 | THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS Related Patents View Abstract: The present disclosure provides for compounds of the general Formula (I) … |
ABBVIE | 2024-04-18 | 2025-03-13 | |
| 60 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3′,2′:5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS Related Patents View Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R have any of the values defined in the specification, and pharmaceutically acceptable salts … |
ABBVIE | 2024-03-05 | 2025-02-27 | |
| 61 | Methods for Treating HCV Related Patents View Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 … |
ABBVIE | 2024-11-04 | 2025-02-20 | |
| 62 | METHODS OF TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE Related Patents View Abstract: The invention described herein relates to methods of treating HIV infection comprising administering an anti-PD-1 monoclonal antibody and/or an anti-α4β7 monoclonal antibody. … |
ABBVIE | 2024-08-15 | 2025-02-20 | |
| 63 | METHODS OF TREATING ALOPECIA ARAETA Related Patents View Abstract: The present disclosure is directed to methods for treating alopecia areata (AA) using the selective JAK1 inhibitor upadacitinib. … |
ABBVIE | 2024-08-07 | 2025-02-13 | |
| 64 | Process for Manufacturing Pibrentasvir Active Drug Substance Related Patents View Abstract: The present invention relates to compositions of pibrentasvir, drug products thereof, and processes and intermediates for the preparation thereof. … |
ABBVIE | 2024-02-28 | 2025-02-13 | |
| 65 | ANTI-PAPP-A ANTIBODIES AND METHODS OF USE THEREOF Related Patents View Abstract: Provided herein are anti-PAPP-A antibodies. Also provided are methods of using such antibodies to treat PAPP-A associated disorders such as kidney disease. … |
CALICO LIFE SCIENCES et. al. | 2024-10-22 | 2025-02-06 | |
| 66 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: The present invention provides for compounds of Formula (I) wherein R , has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as … |
CALICO LIFE SCIENCES et. al. | 2022-11-10 | 2025-02-06 | |
| 67 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The present disclosure provides SEZ6 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs. … |
ABBVIE | 2024-10-15 | 2025-01-30 | |
| 68 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 1 Related Patents View Abstract: The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of … |
ABBVIE | 2024-10-11 | 2025-01-30 | |
| 69 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS Related Patents View Abstract: The present disclosure relates to neurotoxin serotype A (BoNT/A) compositions with a plurality of 900 kDa neurotoxin serotype A (BoNT/A) complex species. Provided herein are … |
ABBVIE | 2024-09-19 | 2025-01-30 | |
| 70 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS Related Patents View Abstract: The present disclosure relates to neurotoxin serotype A (BoNT/A) compositions with a plurality of 900 kDa neurotoxin serotype A (BoNT/A) complex species. Provided herein are … |
ABBVIE | 2024-09-19 | 2025-01-30 | |
| 71 | Methods of Administering Elagolix Related Patents View Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In … |
ABBVIE | 2024-10-01 | 2025-01-16 | |
| 72 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Related Patents View Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is … |
ABBVIE; GENENTECH; WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH | 2024-09-12 | 2025-01-16 | |
| 73 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: The present invention provides for compounds of Formula (I) (I); wherein R , X, and Z have any of the values defined herein, and pharmaceutically acceptable salts thereof, that … |
CALICO LIFE SCIENCES et. al. | 2022-11-10 | 2025-01-16 | |
| 74 | PHARMACEUTICAL FORMULATIONS FOR TREATING ENDOMETRIOSIS, UTERINE FIBROIDS, POLYCYSTIC OVARY SYNDROME OR ADENOMYOSIS Related Patents View Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. … |
ABBVIE et. al. | 2024-09-06 | 2025-01-02 | |
| 75 | ANTI-HUMAN CD33 BET DEGRADER ANTIBODY-DRUG CONJUGATES Related Patents View Abstract: The present disclosure provides anti-human CD33 bromo- and extra-terminal domain degrader antibody-drug conjugates, including compositions and methods of using such antibody-drug … |
ABBVIE | 2024-05-31 | 2025-01-02 | |
| 76 | METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES Related Patents View Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to … |
ABBVIE | 2024-09-09 | 2024-12-26 | |
| 77 | ENZYME COMPOSITIONS WITH REDUCED VIRAL AND MICROBIAL CONTAMINATION Related Patents View Abstract: The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for … |
ABBVIE | 2024-03-11 | 2024-12-26 | |
| 78 | Degrader Compounds and Uses Thereof Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or … |
CALICO LIFE SCIENCES et. al. | 2022-06-21 | 2024-12-26 | |
| 79 | METHODS FOR TREATING ANEMIA OF KIDNEY DISEASE Citation: 2 Related Patents View Abstract: Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. … |
DISC MEDICINE; ABBVIE DEUTSCHLAND; ABBVIE | 2022-11-16 | 2024-12-19 | |
| 80 | TREATMENT OF MAJOR DEPRESSIVE DISORDER Related Patents View Abstract: The present disclosure provides methods for the treatment of major depressive disorder by administering cariprazine or a pharmaceutically acceptable salt thereof. … |
ABBVIE et. al. | 2024-02-09 | 2024-12-05 | |
| 81 | TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB Related Patents View Abstract: Provided are methods for treating various spondyloarthritic conditions, including types of axial spondyloarthritis (axS-pA), with the JAK1 inhibitor, upadacitinib free base or … |
ABBVIE | 2022-10-05 | 2024-12-05 | |
| 82 | METHODS OF TREATING VITILIGO WITH UPADACITINIB Related Patents View Abstract: The present disclosure is directed to methods for treating vitiligo using the selective JAK1 inhibitor upadacitinib. … |
ABBVIE | 2024-05-22 | 2024-11-28 | |
| 83 | SYSTEMS AND METHODS FOR GENERATING LONGITUDINAL DATA PROFILES FROM MULTIPLE DATA SOURCES Related Patents View Abstract: A computer-implemented method for generating a longitudinal data profile from multiple disparate data sources is provided. The method includes storing, at a central data hub, … |
ABBVIE | 2024-05-17 | 2024-11-21 | |
| 84 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 1 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl) pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2024-07-17 | 2024-11-14 | |
| 85 | NICOTINAMIDE RIPK1 INHIBITORS Related Patents View Abstract: Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further … |
ABBVIE | 2024-03-18 | 2024-10-31 | |
| 86 | Bromodomain Inhibitors Related Patents View Abstract: The present invention provides for compounds of formula (I) wherein R , R , R , R , R , X , and X have any of the values defined in the specification, and pharmaceutically … |
ABBVIE | 2023-11-21 | 2024-10-31 | |
| 87 | DOSING REGIMENS FOR USE IN PREVENTING RELAPSE OF ACUTE MYELOID LEUKEMIA FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE Related Patents View Abstract: The invention described herein relates to relates to dosing methods for a human subject with acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell … |
ABBVIE | 2024-04-04 | 2024-10-24 | |
| 88 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 1 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl) pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2024-06-05 | 2024-09-26 | |
| 89 | METHODS OF TREATING PEDIATRIC PATIENTS WITH UPADACITINIB Related Patents View Abstract: The present disclosure is directed to methods for treating disease in pediatric patients with the JAK1 selective inhibitor upadacitinib. The diseases and disorders include … |
ABBVIE | 2024-03-21 | 2024-09-26 | |
| 90 | MODULATORS OF THE INTEGRATED STRESS PATHWAY Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions. … |
CALICO LIFE SCIENCES et. al. | 2023-06-06 | 2024-09-19 | |
| 91 | METHODS OF ADMINISTERING ELAGOLIX Related Patents View Abstract: The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes … |
ABBVIE | 2023-10-17 | 2024-09-12 | |
| 92 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Related Patents View Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is … |
ABBVIE | 2023-08-15 | 2024-08-29 | |
| 93 | MEDICINE CONTAINER, METHOD OF ASSEMBLING THE CONTAINER, AND METHOD OF MANUFACTURING THE CONTAINER Related Patents View Abstract: A medicine container that includes a container body comprising a bottom wall that at least partially defines an interior of the container body, wherein the bottom wall comprises a … |
ABBVIE | 2024-03-11 | 2024-08-22 | |
| 94 | PUMP, MOTOR AND ASSEMBLY FOR BENEFICIAL AGENT DELIVERY Related Patents View Abstract: Pump includes a motor, a cam shaft coupled to the motor for rotation about a longitudinal axis of the cam shaft, the cam shaft having at least one radially-outward projection … |
ABBVIE | 2024-01-31 | 2024-08-22 | |
| 95 | Clostridium botulinum Serotype A Neurotoxin (BoNT/A) Sequence Variants Related Patents View Abstract: Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT/A) complex comprising a 150 kDa BoNT/A. Said 150 kDa BoNT/A is in the form of a … |
ABBVIE | 2024-01-19 | 2024-08-22 | |
| 96 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS Citation: 2 Related Patents View Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders. … |
ABBVIE DEUTSCHLAND et. al. | 2024-04-17 | 2024-08-08 | |
| 97 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS Related Patents View Abstract: The present disclosure relates to neurotoxin serotype A (BoNT/A) compositions with a plurality of 900 kDa neurotoxin serotype A (BoNT/A) complex species. Provided herein are … |
ABBVIE | 2024-01-19 | 2024-07-25 | |
| 98 | Methods for Treating HCV Related Patents View Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 … |
ABBVIE | 2024-03-22 | 2024-07-11 | |
| 99 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE Related Patents View Abstract: The present disclosure provides for compounds of Formula (I) … |
ABBVIE et. al. | 2023-08-03 | 2024-07-11 | |
| 100 | TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB Related Patents View Abstract: Provided are methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis … |
ABBVIE | 2023-08-04 | 2024-07-04 | |
| 101 | ANTI-EGFR ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. … |
ABBVIE | 2023-07-10 | 2024-06-20 | |
| 102 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Related Patents View Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from … |
GENENTECH; HOFFMANN-LA ROCHE; ABBVIE | 2023-12-08 | 2024-06-06 | |
| 103 | Dosing Regimens for Elagolix Related Patents View Abstract: The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for … |
ABBVIE | 2023-10-25 | 2024-06-06 | |
| 104 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 1 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-12-05 | 2024-05-30 | |
| 105 | SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS Related Patents View Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The … |
ABBVIE et. al. | 2023-07-14 | 2024-05-30 | |
| 106 | MODULATORS OF THE INTEGRATED STRESS PATHWAY Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions. … |
CALICO LIFE SCIENCES et. al. | 2023-06-06 | 2024-05-30 | |
| 107 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 2 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-12-05 | 2024-05-23 | |
| 108 | MODULATORS OF THE INTEGRATED STRESS PATHWAY Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions. … |
CALICO LIFE SCIENCES et. al. | 2023-05-26 | 2024-05-23 | |
| 109 | ANTI-PAPP-A ANTIBODIES AND METHODS OF USE THEREOF Related Patents View Abstract: Provided herein are anti-PAPP-A antibodies. Also provided are methods of using such antibodies to treat PAPP-A associated disorders such as kidney disease. … |
CALICO LIFE SCIENCES et. al. | 2023-11-14 | 2024-05-16 | |
| 110 | Pyrrolidine Main Protease Inhibitors as Antiviral Agents Related Patents View Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds. … |
ABBVIE | 2023-10-12 | 2024-05-16 | |
| 111 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER Related Patents View Abstract: Drug delivery reservoir cassette for a pump is provided. The cassette includes a cassette housing having a front surface, a back surface and lateral sidewalls, the cassette … |
ABBVIE | 2023-10-18 | 2024-05-02 | |
| 112 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA Related Patents View Abstract: The present disclosure is directed to methods for treating hidradenitis suppurativa (HS) using the selective JAK1 inhibitor upadacitinib. … |
ABBVIE | 2023-09-28 | 2024-04-18 | |
| 113 | Methods for Treating HCV Related Patents View Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 … |
ABBVIE | 2023-12-11 | 2024-04-11 | |
| 114 | Anti-EGFR Antibody-Drug Conjugates Related Patents View Abstract: The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such … |
ABBVIE | 2023-11-10 | 2024-04-11 | |
| 115 | ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF Related Patents View Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable … |
ABBVIE | 2023-05-19 | 2024-04-11 | |
| 116 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Related Patents View Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from … |
GENENTECH; HOFFMANN-LA ROCHE; ABBVIE | 2023-11-10 | 2024-04-04 | |
| 117 | PYRIMIDINES FOR DEGRADING BRUTON’S TYROSINE KINASE Citation: 1 Related Patents View Abstract: The present invention provides for compounds of formula (I) wherein R , R , R , R , R , and R , are as defined herein, and pharmaceutically acceptable salts thereof, that are … |
ABBVIE | 2023-03-21 | 2024-04-04 | |
| 118 | SUBCUTANEOUSLY ADMINISTERED TREATMENTS FOR ADVANCED PARKINSON’S DISEASE Citation: 1 Related Patents View Abstract: The present disclosure relates to safe and effective subcutaneously administered treatments for advanced Parkinson’s disease. … |
ABBVIE | 2022-10-27 | 2024-03-28 | |
| 119 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA Related Patents View Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein … |
GENENTECH; ABBVIE | 2023-11-03 | 2024-03-21 | |
| 120 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The present disclosure provides SEZ6 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs. … |
ABBVIE | 2023-08-25 | 2024-03-21 | |
| 121 | Methods for Treating HCV Related Patents View Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 … |
ABBVIE | 2023-11-03 | 2024-03-14 | |
| 122 | Solid Pharmaceutical Compositions for Treating HCV Related Patents View Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first … |
ABBVIE | 2023-02-08 | 2024-03-07 | |
| 123 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same Related Patents View Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the … |
ABBVIE | 2022-05-31 | 2024-02-22 | |
| 124 | COCRYSTALS OF UPADACITINIB Related Patents View Abstract: The disclosure relates to cocrystals of solid state forms of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide … |
ABBVIE | 2023-10-06 | 2024-02-08 | |
| 125 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Related Patents View Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is … |
ABBVIE; GENENTECH; WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH | 2023-09-06 | 2024-02-08 | |
| 126 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS Related Patents View Abstract: The present disclosure is directed to methods for treating systemic lupus erythematosus (SLE) using the selective JAK1 inhibitor upadacitinib. … |
ABBVIE | 2023-07-27 | 2024-02-08 | |
| 127 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 2 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-06-02 | 2024-02-01 | |
| 128 | CARBIDOPA AND L-DOPA PRODRUGS ANDMETHODS OF USE Citation: 1 Related Patents View Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods … |
ABBVIE | 2023-06-14 | 2024-01-25 | |
| 129 | MODULATORS OF THE INTEGRATED STRESS PATHWAY Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. … |
CALICO LIFE SCIENCES et. al. | 2023-09-07 | 2024-01-18 | |
| 130 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 7 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-09-18 | 2024-01-11 | |
| 131 | SYSTEMS AND METHODS FOR IDENTIFYING PROTEIN AGGREGATES IN BIOTHERAPEUTICS Related Patents View Abstract: Systems and methods for inspecting particles in a liquid beneficial agent are provided. Inspecting particles in a liquid beneficial agent includes selectively illuminating at … |
ABBVIE | 2023-07-03 | 2024-01-11 | |
| 132 | MODULATORS OF THE INTEGRATED STRESS PATHWAY Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. … |
CALICO LIFE SCIENCES et. al. | 2023-09-07 | 2024-01-04 | |
| 133 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Citation: 3 Related Patents View Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from … |
GENENTECH; HOFFMANN-LA ROCHE; ABBVIE | 2023-09-07 | 2024-01-04 | |
| 134 | Methods of Administering Elagolix Related Patents View Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In … |
ABBVIE | 2023-09-06 | 2023-12-28 | |
| 135 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 7 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-08-21 | 2023-12-14 | |
| 136 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE Related Patents View Abstract: The present disclosure provides for compounds of Formula (I) wherein A , A , A , A , A , A , A , R , R , R , R , R , R , R , R , R , R , W, X, and Y have any of the values defined … |
ABBVIE et. al. | 2022-10-12 | 2023-12-14 | |
| 137 | Methods for Treating HCV Related Patents View Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 … |
ABBVIE | 2023-08-11 | 2023-11-30 | |
| 138 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 7 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-07-28 | 2023-11-23 | |
| 139 | ANTI-C-MET ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs. … |
ABBVIE | 2023-03-09 | 2023-11-23 | |
| 140 | TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB Related Patents View Abstract: Provided are methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis … |
ABBVIE | 2022-10-12 | 2023-11-16 | |
| 141 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 6 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-06-06 | 2023-11-02 | |
| 142 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 6 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-06-06 | 2023-10-19 | |
| 143 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 6 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-06-06 | 2023-10-12 | |
| 144 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE Related Patents View Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer. … |
ABBVIE BIOTHERAPEUTICS; ABBVIE | 2023-02-22 | 2023-10-12 | |
| 145 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 6 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-06-02 | 2023-10-05 | |
| 146 | THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS Related Patents View Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R , R , R , R , R , R , R , R , R , and Ring A have any of the values defined in the … |
ABBVIE | 2023-03-30 | 2023-10-05 | |
| 147 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 7 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-03-01 | 2023-10-05 | |
| 148 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 7 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-02-27 | 2023-10-05 | |
| 149 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT Related Patents View Abstract: Salts and crystalline forms of … |
ABBVIE | 2022-10-18 | 2023-10-05 | |
| 150 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 7 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-02-27 | 2023-09-28 | |
| 151 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING Related Patents View Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an … |
ABBVIE | 2023-05-15 | 2023-09-14 | |
| 152 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER Related Patents View Abstract: Drug delivery reservoir for delivery of a beneficial agent to a user includes a drug delivery reservoir housing having a fluid reservoir defined therein. The drug delivery … |
ABBVIE | 2023-04-28 | 2023-09-14 | |
| 153 | Anti-Viral Compounds Related Patents View Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions … |
ABBVIE | 2022-09-09 | 2023-09-14 | |
| 154 | Methods of Treating Heavy Menstrual Bleeding Related Patents View Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an … |
ABBVIE | 2023-05-15 | 2023-09-07 | |
| 155 | Methods of Administering Elagolix Related Patents View Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In … |
ABBVIE | 2023-05-05 | 2023-08-31 | |
| 156 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 7 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-03-01 | 2023-08-31 | |
| 157 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Citation: 3 Related Patents View Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from … |
GENENTECH; HOFFMANN-LA ROCHE; ABBVIE | 2023-03-28 | 2023-08-17 | |
| 158 | PHARMACEUTICAL FORMULATIONS FOR TREATING ENDOMETRIOSIS, UTERINE FIBROIDS, POLYCYSTIC OVARY SYNDROME OR ADENOMYOSIS Related Patents View Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. … |
ABBVIE et. al. | 2023-02-13 | 2023-08-17 | |
| 159 | METHOD OF ADMINISTERING UPADACITINIB TO AVOID ADVERSE DRUG INTERACTIONS AND EFFECTS Citation: 8 Related Patents View Abstract: The present disclosure is directed to methods for treating immunological diseases and disorders with upadacitinib. The methods include adjusting the dose of upadacitinib in … |
ABBVIE | 2023-03-28 | 2023-07-27 | |
| 160 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors Related Patents View Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R have any of the values defined in the specification, and pharmaceutically acceptable salts … |
ABBVIE | 2023-01-19 | 2023-07-27 | |
| 161 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Citation: 3 Related Patents View Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from … |
GENENTECH; HOFFMANN-LA ROCHE; ABBVIE | 2023-01-20 | 2023-07-20 | |
| 162 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 9 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine carboxamide, solid … |
ABBVIE | 2023-03-01 | 2023-07-13 | |
| 163 | METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES Related Patents View Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to … |
ABBVIE | 2023-02-03 | 2023-07-13 | |
| 164 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 9 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-03-01 | 2023-06-29 | |
| 165 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 9 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-03-01 | 2023-06-29 | |
| 166 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 9 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-01-06 | 2023-06-29 | |
| 167 | ANTI-AMYLOID BETA ANTIBODIES AND METHODS OF USING THE SAME Related Patents View Abstract: The present inventive concept is related to antibodies, such as recombinant humanized and monoclonal antibodies, methods of making antibodies, and methods of using antibodies, … |
ABBVIE | 2022-10-28 | 2023-06-29 | |
| 168 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 6 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2023-01-06 | 2023-06-15 | |
| 169 | DOSING REGIMENS FOR USE IN TREATING RELAPSED AND REFRACTORY MULTIPLE MYELOMA WITH VENETOCLAX Related Patents View Abstract: The invention described herein relates to dosing methods for treating relapsed and refractory multiple myeloma (RRMM) in a human subject comprising administering to the subject … |
ABBVIE | 2022-12-08 | 2023-06-15 | |
| 170 | BROMODOMAIN INHIBITORS Related Patents View Abstract: The present invention provides for compounds of formula (I) … |
ABBVIE | 2022-06-30 | 2023-05-25 | |
| 171 | TREATMENT OF MAJOR DEPRESSIVE DISORDER Related Patents View Abstract: The present disclosure provides methods for the treatment of major depressive disorder by administering cariprazine or a pharmaceutically acceptable salt thereof. … |
ABBVIE et. al. | 2022-10-28 | 2023-05-18 | |
| 172 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Related Patents View Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is … |
ABBVIE; GENENTECH; WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH | 2022-10-07 | 2023-05-11 | |
| 173 | MODULATORS OF THE INTEGRATED STRESS PATHWAY Citation: 1 Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions. … |
CALICO LIFE SCIENCES et. al. | 2022-06-14 | 2023-05-11 | |
| 174 | INJECTION DEVICE WITH END OF DOSE INDICATOR Citation: 1 Related Patents View Abstract: An injection device includes a housing having an internal volume and a viewing portion. A movable seal is disposed in the internal volume and is movable from an initial position … |
ABBVIE | 2022-08-26 | 2023-05-04 | |
| 175 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. … |
ABBVIE | 2022-06-08 | 2023-05-04 | |
| 176 | NICOTINAMIDE RIPK1 INHIBITORS Related Patents View Abstract: Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further … |
ABBVIE | 2022-08-08 | 2023-04-27 | |
| 177 | Levodopa and Carbidopa Intestinal Gel and Methods of Use Related Patents View Abstract: The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson’s disease … |
ABBVIE | 2022-08-03 | 2023-04-27 | |
| 178 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. … |
ABBVIE | 2022-04-27 | 2023-04-20 | |
| 179 | IL-1 Binding Proteins Related Patents View Abstract: Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting … |
ABBVIE | 2022-04-29 | 2023-04-13 | |
| 180 | METHODS OF TREATING PARKINSON’S DISEASE Citation: 1 Related Patents View Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods … |
ABBVIE | 2022-10-24 | 2023-04-06 | |
| 181 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 11 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2022-09-23 | 2023-02-23 | |
| 182 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 11 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2022-09-23 | 2023-02-23 | |
| 183 | ANTI-CCR8 ANTIBODIES Citation: 1 Related Patents View Abstract: The present disclosure provides anti-CCR8 antibodies, including compositions and methods of using such antibodies. … |
ABBVIE | 2022-07-27 | 2023-02-16 | |
| 184 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA Citation: 1 Related Patents View Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein … |
GENENTECH; ABBVIE | 2022-09-15 | 2023-01-26 | |
| 185 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Related Patents View Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or … |
CALICO LIFE SCIENCES et. al. | 2022-06-16 | 2023-01-19 | |
| 186 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA Citation: 1 Related Patents View Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein … |
GENENTECH; ABBVIE | 2022-06-07 | 2023-01-05 | |
| 187 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER Related Patents View Abstract: A device for delivering a beneficial agent is provided and generally includes a cassette, a pump, and a delivery tube. The pump includes a pump housing containing a pump assembly … |
ABBVIE | 2022-05-20 | 2022-12-01 | |
| 188 | VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH AZACITIDINE Citation: 1 Related Patents View Abstract: The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine for treating myelodysplastic syndromes … |
ABBVIE | 2022-05-10 | 2022-12-01 | |
| 189 | ANTI-C-MET ANTIBODY DRUG CONJUGATES Related Patents View Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs. … |
ABBVIE | 2022-04-29 | 2022-12-01 | |
| 190 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Citation: 3 Related Patents View Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from … |
GENENTECH; HOFFMANN-LA ROCHE; ABBVIE | 2022-06-07 | 2022-11-24 | |
| 191 | VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH A CYP3A INHIBITOR AND AZACITIDINE Citation: 1 Related Patents View Abstract: The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine and a CYP3A inhibitor for treating … |
ABBVIE | 2022-05-10 | 2022-11-24 | |
| 192 | ISOLATION AND PURIFICATION OF ANTI-IL-13 ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY Related Patents View Abstract: Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition … |
ABBVIE | 2022-05-17 | 2022-10-27 | |
| 193 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 19 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2022-05-27 | 2022-09-29 | |
| 194 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 18 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2022-05-27 | 2022-09-22 | |
| 195 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 19 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2022-05-27 | 2022-09-22 | |
| 196 | METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES Citation: 1 Related Patents View Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to … |
ABBVIE | 2022-05-10 | 2022-09-08 | |
| 197 | METHODS OF TREATING CROHN’S DISEASE AND ULCERATIVE COLITIS Citation: 22 Related Patents View Abstract: The present disclosure is directed to methods for treating Crohn’s disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn’s … |
ABBVIE | 2022-04-28 | 2022-09-01 | |
| 198 | MEDICATION PACKAGING AND DISPENSING SYSTEM Related Patents View Abstract: A medication packaging and dispensing system is provided. The system may include a plurality of medication booklets containing medication and a tray that is configured to retain … |
ABBVIE | 2022-05-10 | 2022-08-25 | |
| 199 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Citation: 19 Related Patents View Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid … |
ABBVIE | 2022-05-02 | 2022-08-25 | |
| 200 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE Related Patents View Abstract: The present disclosure provides for compounds of Formula (I) wherein A , A , A , A , A , A , A , R , R , R , R , R , R , R , R , R , R , W, X, and Y have any of the values defined … |
ABBVIE et. al. | 2022-04-22 | 2022-08-18 |